Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Recurrent × Dasatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1 Genitourinary 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 53 Precursor Cell Lymphoblastic Leukemia-Lymphoma 44 Leukemia, Myeloid, Chronic-Phase 31 Leukemia 24 Leukemia, Myeloid, Acute 17 Breast Neoplasms 15 Leukemia, Lymphocytic, Chronic, B-Cell 12 Recurrence 11 Prostatic Neoplasms 11 Neoplasm Metastasis 10 Burkitt Lymphoma 10 Multiple Myeloma 9 Carcinoma, Non-Small-Cell Lung 9 Pancreatic Neoplasms 8 Leukemia, Myeloid, Accelerated Phase 8 Blast Crisis 8 Neoplasms 7 Lymphoma, Non-Hodgkin 7 Glioblastoma 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6 Lung Neoplasms 6 Philadelphia Chromosome 5 Myelodysplastic Syndromes 5 Gliosarcoma 5 Waldenstrom Macroglobulinemia 4 Melanoma 4 Hodgkin Disease 4 Hematologic Neoplasms 4 Glioma 4 Brain Neoplasms 4

Interventions

tempol 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 TEMPOL-H 1 Sirolimus 1 Nelfinavir 1 Metformin 1 Hydroxychloroquine 1 Diet, Protein-Restricted 1 Dasatinib 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05036226 2025-10-06

COAST

Medical University of South Carolina

Phase 1/2 Recruiting

GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡